Helperby Therapeutics Media Coverage

The Drugs Don’t Work

The fight against antibiotic resistance is real and something we all have a responsibility in tackling. As traditional drugs stop working, what steps are being taken now?
26 Sep 2018

Outsmarting The World’s Most Dangerous Superbugs

​Using its antibiotic renewable technology, Helperby Therapeutics is developing a new class of antibiotics with activity against multi drug-resistant bacteria, including strains with transferable resistance to carbapenems and colistin.
27 Jul 2018

Antibiotics & Antimocrobial Resistance (AMR) - A Global Perspective

Antibiotic resistance is at a crossroad. In the world today, deaths in low income countries from Antimicrobial Resistance (AMR) are predicted to rise dramatically by 2050. We know how to stop
21 Jul 2018

Journal for Clinical Studies Reports Helperby’s Phase 1 Results in Brand New Antibiotic

The combination is azidothymidine (AZT), which is a new class antibacterial, and low dose colistin. The combination is active against all three WHO Critical Priority Pathogens. In addition, AZT and
15 Jun 2018

Helperby Therapeutics’ Combination Antibiotic Therapy is Effective Against WHO Critical Priority Pathogen in Phase I Study

Helperby Therapeutics has announced Phase I results on the tolerability, pharmacokinetics, pharmacodynamics and efficacy of AZT and colistin both alone and as a combined therapy, against multi-drug resistant Enterobacteriaceae (CRE),
15 Jun 2018

BusinessWire Feature Phase 1 Results for New Critical Priority Antibiotic from Helperby Therapeutics

The combination is azidothymidine (AZT), a new class antibacterial, and low dose colistin. The combination is active against all three WHO Critical Priority Pathogens. AZT and colistin act synergistically against
01 Jun 2018